Methadone: does it really have low efficacy at micro-opioid receptors?

Area of Science:

• Pharmacology
• Neuroscience
• Molecular Biology

Background:

• Conflicting literature exists regarding methadone's agonist efficacy at micro-opioid receptors (MOPrs).
• Previous studies suggest varying levels of methadone efficacy, leading to confusion.

Purpose of the Study:

• To clarify the relative agonist efficacy of methadone at MOPrs.
• To investigate the mechanisms behind methadone's observed effects on G-protein-gated potassium (GIRK) channels.

Main Methods:

• Guanosine 5'-O-[gamma-thio]triphosphate (GTPgammaS) binding assays were used to assess MOPr activation.
• Studies examined methadone's effects on MOPr activation of GIRK channels.
• Methadone's inhibitory effects on other ion channels, including alpha2-adrenoceptor-activated GIRK and small conductance Ca2+-activated K+ (SK2) channels, were investigated.

Main Results:

• Methadone was confirmed as a full agonist at MOPrs in GTPgammaS binding studies.
• Methadone exhibited low apparent efficacy at MOPr-activated GIRK channels due to direct inhibition of the channels.
• Methadone was found to inhibit alpha2-adrenoceptor-activated GIRK channels and SK2 channels, indicating it is not a specific GIRK channel blocker.

Conclusions:

• Methadone is a full agonist at MOPrs.
• The observed low efficacy in some functional assays is attributed to direct ion channel inhibition, not low intrinsic efficacy at the MOPr.
• Methadone induces MOPr desensitization and internalization, consistent with its role as a full agonist.